Who
Jian Irish
Director and Officer
Company insider
Files Form 4 as: Chief Executive Officer, Metagenomi Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $37K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Apr 2024
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,4792,140 at $1.16 | filing |
| 8 Sep 2026filed 10 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,4822,140 at $1.16 | filing |
| 5 Jun 2026filed 10 Jun 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,8543,737 at $1.30 | filing |
| 5 Jun 2026filed 10 Jun 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,8583,737 at $1.30 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —276,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —276,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,5711,607 at $1.60 | filing |
| 5 Mar 2026filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,5711,607 at $1.60 | filing |
| 5 Dec 2025filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code G | —228,462 at $0.00 | filing |
| 5 Dec 2025filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code G | —228,462 at $0.00 | filing |
| 5 Dec 2025filed 8 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,8361,602 at $1.77 | filing |
| 1 Dec 2025filed 1 Dec 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 1 Dec 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | $60K37,500 at $1.60 | filing |
| 1 Dec 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | $338K211,000 at $1.60 | filing |
| 5 Sep 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,9001,602 at $1.81 | filing |
| 6 Jun 2025filed 9 Jun 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K6,390 at $1.75 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.